Kyle Holen | SVP, Head of Development, Therapeutics and Oncology

Kyle Holen, SVP, Head of Development, Therapeutics and Oncology, Moderna

As a medical oncologist, Kyle saw first hand the devastating effects that serious disease can have on patients and their families. This is why, after completing medical school, residency, and fellowship, he dedicated his life’s work to finding better therapies for those who desperately need them.  He started by conducting research, education, and patient care as an associate professor at the University of Wisconsin. He continued his mission by leading multiple clinical research teams at AbbVie, a bio pharmaceutical company.  Kyle is currently the head of development at Moderna, responsible for the clinical research programs in oncologic, rare, cardiovascular, pulmonary, and autoimmune diseases.


Day 2 - Wednesday 3rd April @ 16:40

mRNA-4157 overview: the impact of a cancer vaccine on those with melanoma – Title TBC

Day 2 - Wednesday 3rd April @ 17:10

Panel: Exploring the future prospects of cancer vaccines

  • Exploring the role and prospects of (neo)adjuvant cancer vaccines in the therapeutic landscape: adjuvant versus neoadjuvant, prevention of reoccurrence vs truly therapeutic, value in metastatic disease
  • Indications & immune characteristics: hot versus cold tumors & TME
  • Is there potential for off-the-shelf vaccines? What might this strategy look like?
last published: 30/Nov/23 11:25 GMT

back to speakers